| ALTIMMUNE INC. DL-,0001 |
| USA |
| Gesundheit |
| US02155H2004 / A2N5Z6 |
| 3G0 (Frankfurt) / ALT (NASDAQ) |
| FRA:3G0, ETR:3G0, 3G0:GR, NASDAQ:ALT |
| - |
| https://altimmune.com/ |
|
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based therapeutics for obesity, metabolic diseases, and liver diseases. Its lead product candidate, pemvidutide, is a novel GLP-1/glucagon dual receptor agonist designed..
>Volltext.. |
| 394.47 Mio. EUR |
| 191.19 Mio. EUR |
| 0.03 Mio. EUR |
| -80.4 Mio. EUR |
| -75.05 Mio. EUR |
| -0.87 EUR |
| 30.4 Mio. EUR |
| 37.31 Mio. EUR |
| -57.53 Mio. EUR |
| 18.24 |
| 80.69% |
| 18.32% |
| - |
| - |
| - |
| 20.01.17 - 224502.93€ |
| ALTIMMUNE |
| 23.04.26 |
|